Lilly Signs a Global Research and License Collaboration with Dicerna for ~$550M
Shots:
- Dicerna will receive $100M upfront plus ~$350M as development and commercialization milestones with tiered royalties and equity investment of $100M
- Lilly will get hold of Dicerna’s GalXC RNAi technology as well as development and commercialization rights to new developed drugs in fields of cardio-metabolic diseases- neurodegeneration and pain
- Dicerna’s GalXC RNAi technology is an attempt to enhance development of next-generation RNAi-based therapeutics- with SC delivery of therapies across multiple therapy areas- including rare diseases- chronic liver diseases- cardiovascular diseases and viral infectious diseases
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
